Share
.webp)
.webp)
.webp)
.webp)
John Bencich
AEON Biopharma, Inc., a company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA), has appointed John Bencich as Chief Financial Officer.
The appointment comes at a pivotal time as AEON progresses toward key regulatory milestones and prepares for its next phase of growth.
Bencich brings more than 25 years of leadership experience across corporate strategy, capital markets, and business development within emerging growth and publicly traded companies. His expertise includes executing financing strategies, supporting regulatory advancement, and driving long-term value creation.
Most recently, Bencich served as Chief Executive Officer of Achieve Life Sciences, where he led capitalization efforts and contributed to significant market value growth. During his tenure, he also oversaw clinical and regulatory milestones, strengthened the company’s intellectual property portfolio, and advanced commercial and business development initiatives.
Earlier in his career, Bencich held Chief Financial Officer roles at OncoGenex Pharmaceuticals, Integrated Diagnostics, Allozyne, and Trubion Pharmaceuticals. Across these roles, he supported multiple financings, strategic transactions, and public company readiness initiatives.
Bencich holds a Bachelor of Accountancy from University of San Diego and an MBA from Seattle University.
